GALWAY, Ireland, February 17, 2010 /PRNewswire/ -- Cappella (http://www.cappella-med.com/), Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced the addition of Mr. Eamonn Hobbs to the Board of Directors ( http://www.cappella-med.eu/index.php?option=com_content&view=article&id=181:b oard-of-directors&catid=4). According to Mr. Wolfgang Oster, MD, PhD, Chairman of the Board and Managing Partner at PolyTechnos Venture-Partners GmbH, “Eamonn’s wealth of expertise and solid track record of success in our medical device field makes him a formidable source of wisdom and judgement for the road ahead of Cappella. The company’s commercial programs and global market expansion will greatly benefit from Mr Hobbs’ insights.”
Mr. Eamonn Hobbs, President, CEO, & Director of Delcath Systems, Inc. is an entrepreneurial senior executive with over 25 years of medical device experience and demonstrated success in profitable business creation, general management, sales and marketing and product development. When asked to comment on his recent appointment, Mr. Hobbs stated, “I am delighted to join Cappella’s Board of Directors and support the cause of this company which is all about addressing a substantial unmet medical need. Whereas long under-diagnosed and under-served, bifurcational lesions have now attracted the much deserved attention of the medical community and I am convinced that Cappella has put the best team on the field to tackle the challenge. I am thrilled to work with Dr. Art Rosenthal and our Board of Directors to deliver this technology to patients in need.”
About Cappella, Inc.
Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella’s initial product, the Sideguard(R) (http://www.cappella-med.eu/index.php?option=com_content&view=article&id=1&It emid=2) Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. More importantly, it allows the preferred stent of choice for the main vessel. An optimal stent design specific to the anatomy of the sidebranch, combined with the qualities of Nitinol now provide a dynamic solution for treating sidebranch disease. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For more information, see: http://www.cappella-med.com.
(Due to the length of some of the URLs in this release, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)
Links: Cappella : http://www.cappella-med.com/
CONTACT: Contact: Claire Marie Gigon, Cappella Medical Devices Limited,
Tel: +41-(0)79-374-57-65, Email: cmgigon@cappella.ie
